Showing 9411-9420 of 20873 results for "".
Challenges of Implementing Evidence-Based Guidance for IgA Nephropathy
https://reachmd.com/programs/kdigo-conversations-nephrology/challenges-of-implementing-evidence-based-guidance-for-iga-nephropathy/37118/In this episode of KDIGO Conversations in Nephrology, host Dr. Dana Rizk welcomes Dr. Suneel Udani to discuss the challenges and opportunities of adopting the updated KDIGO guidelines for IgA nephropathy (IgAN). Their conversation highlights a shift in therapeutic goals and a new paradigm of simultaAdvances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
https://reachmd.com/programs/neurofrontiers/program-name/36465/Over the past two decades, Alzheimer’s diagnosis has transformed from uncertain, exclusion-based methods to more accurate detection of disease pathology. With the advent of amyloid PET tracers, cerebrospinal fluid and plasma biomarkers like p-tau 217, and the promise of AI-driven imaging analysis, cThe Far-Reaching Impacts of Psoriasis: Understanding and Mitigating Risks
https://reachmd.com/programs/dermconsult/the-far-reaching-impacts-of-psoriasis-understanding-and-mitigating-risks/32452/Hear how psoriasis can impact a patient’s health beyond their skin and how to best support them to improve outcomes and minimize risks.Genetics in Psoriasis: Impacts on Risk, Comorbidities, and Care
https://reachmd.com/programs/frontlines-psoriasis/genetics-in-psoriasis-impacts-on-risk-comorbidities-and-care/32435/Genetic insights are reshaping how we understand the development and comorbidities of psoriasis, as well as treatment response in patients. Hear Dr. Audrey Bui discuss how genetic variants influence risks for certain conditions, how they may predict response to therapies like methotrexate, ustekinumOne Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
https://reachmd.com/programs/project-oncology/one-year-or-two-dante-trial-explores-immunotherapy-duration-in-metastatic-melanoma/33002/The DANTE phase III trial investigated if stopping anti–PD-1 therapy at one year yields comparable outcomes to longer treatment in metastatic melanoma. Read more about the findings and their potential clinical implications.Personalizing Prostate Cancer Surveillance: Insights from Canary PASS
https://reachmd.com/programs/frontlines-prostate-cancer/personalizing-prostate-cancer-surveillance-insights-from-canary-pass/32224/For patients with early-stage prostate cancer, routine clinical variables like Gleason scores or PSAs have their limits. The Canary Prostate Active Surveillance Study (Canary PASS) is reshaping our management approach through improved risk stratification. Dr. Lisa Newcomb joins us to explain the finRecognizing and Addressing Rheumatic irAEs from Cancer Immunotherapies
https://reachmd.com/programs/living-rheum/recognizing-and-addressing-rheumatic-iraes-from-cancer-immunotherapies/32791/Patients who are receiving immunotherapy for cancer sometimes develop significant autoimmune complications, which can be fatal. Join Dr. Laura Cappelli, Associate Professor of Medicine and Oncology at the Johns Hopkins University School of Medicine, as she explains how multidisciplinary collaboratioMasterclasses in Dermatology: The Importance of Interdisciplinary Teaching
https://reachmd.com/conferences/masterclasses-in-dermatology-2025/masterclasses-in-dermatology-the-importance-of-interdisciplinary-teaching/33021/Masterclasses in Dermatology 2025 course directors Alice Gottlieb, MD, a dermatologist and rheumatologist at Mount Sinai, and Joseph Merola, MD, MMSc, chair and professor of dermatology at UT Southwestern Medical Center in Dallas, talk about the value of interdisciplinary education and collaborationSpotting the Signs: Early Identification and Management of Schizophrenia
https://reachmd.com/programs/frontlines-schizophrenia/spotting-the-signs-early-identification-and-management-of-schizophrenia/30031/Early signs of schizophrenia can be difficult to detect, but knowing the signs can help improve outcomes. Here’s what you should know.Promising Results for Investigational Antisense Oligonucleotide Treatment for Dravet Syndrome
https://reachmd.com/diseases-diagnoses/epilepsy-seizures/promising-results-for-investigational-antisense-oligonucleotide-treatment-for-dravet-syndrome-1/35435/Joseph Sullivan, MD, Professor, UCSF School of Medicine, San Francisco, CA, describes encouraging results from the SWALLOWTAIL and LONGWING studies of an investigational treatment for individuals with Dravet syndrome, including outcomes related to seizure frequency, cognition, and behavior.